Inhibikase Therapeutics, Inc.

and welcome to InhibitK's therapeutic second quarter 2022 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please sign our conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press the star then one on your touchtone phone. To withdraw your question, please press the star then two. Please note, this event is being recorded. I would now like to turn the conference over to Alex Lobo, CERN Investor Relations.

Please go ahead.

Thank you, and good morning, and welcome to Inhibit Case Therapeutics' second quarter of 2022 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer, and Joseph Fratelloli, Chief Financial Officer. On Friday, Inhibicase issued a press release announcing financial results for the second quarter ended June 30th, 2022. We encourage everyone to read Friday's press release as well as the Inhibicase quarterly report on Form 10-Q for the second quarter of 2022, which has been filed with the SEC. The company's press release and quarterly report are also available on Inhibicase's website at inhibicase.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time sensitive information that is accurate only as of the date of this live broadcast, August 15, 2022. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the FCC at FCC.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law. With that said, I would like to turn the call over to Dr. Milton Warner. Milton, you may begin.